What is Insulet Corporation Annual Revenue?

Insulet Corporation Annual Revenue rose 22.07%, in the last year to $2,071.6 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

What is Insulet Corporation Annual Net Profit?

Insulet Corporation Annual Net Profit rose 102.76% in the last year to $418.3 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

What is Insulet Corporation Price to Earning Ratio?

Insulet Corporation Price to Earning Ratio is 40.05, higher than its sector PE ratio of 28.64.

What is Insulet Corporation Stock Price?

Insulet Corporation Stock Price rose 43.5% and outperformed its sector by 37.98% in the past year.

What is Insulet Corporation Quarterly Revenue?

Insulet Corporation Quarterly Revenue rose 17.2% YoY to $597.5 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

What is Insulet Corporation Quarterly Net profit?

Insulet Corporation Quarterly Net profit fell 2.52% YoY to $100.7 M. Its sector's average net profit growth YoY for the quarter was 32.9%.

What is Insulet Corporation Debt to Equity Ratio?

Insulet Corporation Debt to Equity Ratio of 1.15 is higher than 1. This implies that company assets are financed through debt.

What is Insulet Corporation Return on Equity(ROE)?

Insulet Corporation Return on Equity(ROE) for the last financial year was 43.03%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

What is Insulet Corporation Mutual Fund Holding?

Insulet Corporation Mutual Fund Holding decreased by 0.26% in the last quarter to 101.45.

What is Insulet Corporation Promoter Share Holding?

Insulet Corporation Promoter Share Holding increased by 0.04% in the most recent quarter to 0.45%.

What is Insulet Corporation Interest Coverage Ratio?

Insulet Corporation Interest Coverage Ratio is 8.03, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is Insulet Corporation Institutional Holding?

Insulet Corporation Institutional Holding increased by 0.92% in the last quarter to 102.78.

How is the Insulet Corporation today?

The Insulet Corporation today is trading in the down by -3.33% at 238.57.

How has Insulet Corporation performed historically?

The Insulet Corporation is currently trading down -3.33% on an intraday basis in the past week the index fell -6.07%. The index has been down -13.50% in the past quarter and rose 43.50% in the past year. You can view this in the overview section.

Insulet Corporation XNAS: PODD

Insulet Corporation Live Share Price Today, Share Analysis and Chart

Name: Insulet Corporation: Is Infosys Ltd. worth buying?
Item: Insulet Corporation
Rating: 3.119652625
Author: Trendlyne DVM scores

Expensive Performer

Download real time

238.57 -8.23 (-3.33%)

48.93% Gain from 52W Low

516.2K XNAS Volume

XNAS 21 Apr, 2025 5:30 PM (EDT)

Insulet Corporation Key Metrics

My Metrics

Select

Market Capitalization High in industry Unavailable in chosen country	16,753.8
PE TTM High in industry Unavailable in chosen country	40.1
PEG TTM High in industry Unavailable in chosen country	0.4
Price to Book High in industry Unavailable in chosen country	13.8
Institutional holding current Qtr % High in industry Unavailable in chosen country	102.8
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	17.2
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	22.1
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-2.5
Net Profit TTM Growth % High in industry Unavailable in chosen country	102.8
Operating Profit Margin Qtr % High in industry Unavailable in chosen country	18.3
Operating Profit Margin TTM % High in industry Unavailable in chosen country	14.9
Piotroski Score High in industry Unavailable in chosen country	8
Rel Perf vs Sector quarter% Unavailable in chosen country	-4.7
ROE Annual % High in industry Unavailable in chosen country	43
RoA Annual % High in industry Unavailable in chosen country	14.7

All financials are in USD Million and price data in USD

High Financial Strength

94.4 / 100

Expensive Valuation

19.3 / 100

Technically Neutral

41.4 / 100

Expensive Performer These stocks are strong in quality but with mid-range technical aspects. Their strong financials make them little expensive so choose the right moment to buy them. View Similar Embed DVM

312

1Yr Price target upside is 31%

23 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Strong Buy Zone

1.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Insulet Corporation Stock Price Analysis

Day Price Range -3.3% 1 Day return Unavailable in chosen country	238.6 (LTP) 237.5244.5 LowHigh
Week Price Range -6.1% 1 Week return Unavailable in chosen country	238.6 (LTP) 234.2258 LowHigh
Month Price Range -10.1% 1 Month return Unavailable in chosen country	238.6 (LTP) 234.2276.1 LowHigh
52 Week Price Range 43.5% 1 Year return Unavailable in chosen country	238.6 (LTP) 160.2289.5 LowHigh

View full Share Price History

Insulet Corporation Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Insulet Corporation's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

5.8

Avg. Estimate

4.3

Low Estimate

3.9

High Estimate

5.2

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 26.3% in FY25

Consensus Recommendation

24 ANALYST Recommendations

BUY

The consensus recommendation from 24 analysts for Insulet Corporation is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Insulet Corporation Stock Analysis

Insulet Corporation stock analysis with key metrics, changes, and trends.

Insulet Corporation Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$2,071.6 M	22.07%	positive	Annual Revenue rose 22.07%, in the last year to $2,071.6 M. Its sector's average revenue growth for the last fiscal year was 8.57%.
Annual Net Profit	$418.3 M	102.76%	positive	Annual Net Profit rose 102.76% in the last year to $418.3 M. Its sector's average net profit growth for the last fiscal year was 4.36%.
Price to Earning Ratio	40.05	-	negative	Price to Earning Ratio is 40.05, higher than its sector PE ratio of 28.64.
Stock Price	$238.57	43.5%	positive	Stock Price rose 43.5% and outperformed its sector by 37.98% in the past year.
Quarterly Revenue	$597.5 M	17.2%	positive	Quarterly Revenue rose 17.2% YoY to $597.5 M. Its sector's average revenue growth YoY for the quarter was 8.5%.
Quarterly Net profit	$100.7 M	2.52%	negative	Quarterly Net profit fell 2.52% YoY to $100.7 M. Its sector's average net profit growth YoY for the quarter was 32.9%.
Debt to Equity Ratio	1.15	-	negative	Debt to Equity Ratio of 1.15 is higher than 1. This implies that company assets are financed through debt.
Return on Equity(ROE)	43.03 %	43.03%	positive	Return on Equity(ROE) for the last financial year was 43.03%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.
Mutual Fund Holding	101.45 %	-0.26%	negative	Mutual Fund Holding decreased by 0.26% in the last quarter to 101.45.
Promoter Share Holding	0.45 %	0.04%	positive	Promoter Share Holding increased by 0.04% in the most recent quarter to 0.45%.
Interest Coverage Ratio	8.03	-	positive	Interest Coverage Ratio is 8.03, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
Institutional Holding	102.78 %	0.92%	positive	Institutional Holding increased by 0.92% in the last quarter to 102.78.

VIEW LESS

Loading data..

Insulet Corporation - Company Profile

What does Insulet Corporation do?

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

Insulet Corporation Management structure

All Gross Remunerations are in USD

Mr. Mark N. Field

Senior Vice President and Chief Technology Officer

2025

Gross Remuneration

Year

Mr. Amit Guliani

Group Vice President, Software Engineering and Acting Chief Technology Officer

2025

Gross Remuneration

2024

Gross Remuneration

Year

Insulet Corporation Live Share Price Today, Share Analysis and Chart

48.93% Gain from 52W Low

Insulet Corporation Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Insulet Corporation Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Insulet Corporation Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Insulet Corporation's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to reduce by 26.3% in FY25

Consensus Recommendation

The consensus recommendation from 24 analysts for Insulet Corporation is BUY

Insulet Corporation Stock Analysis

Insulet Corporation stock analysis with key metrics, changes, and trends.

Annual Revenue rose 22.07%, in the last year to $2,071.6 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

Annual Net Profit rose 102.76% in the last year to $418.3 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

Price to Earning Ratio is 40.05, higher than its sector PE ratio of 28.64.

Stock Price rose 43.5% and outperformed its sector by 37.98% in the past year.

Quarterly Revenue rose 17.2% YoY to $597.5 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

Quarterly Net profit fell 2.52% YoY to $100.7 M. Its sector's average net profit growth YoY for the quarter was 32.9%.

Debt to Equity Ratio of 1.15 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE) for the last financial year was 43.03%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.26% in the last quarter to 101.45.

Promoter Share Holding increased by 0.04% in the most recent quarter to 0.45%.

Interest Coverage Ratio is 8.03, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding increased by 0.92% in the last quarter to 102.78.

Insulet Corporation - Company Profile

What does Insulet Corporation do?

Insulet Corporation Management structure

Mr. Mark N. Field

Senior Vice President and Chief Technology Officer

Mr. Amit Guliani

Group Vice President, Software Engineering and Acting Chief Technology Officer

Insulet Corporation Board of directors

Ms. Corinne H. Nevinny

Independent Director

Ms. Shacey Petrovic

Director

Mr. Timothy C. Stonesifer

Director

Ms. Flavia H. Pease

Director

Ms. Elizabeth H. Weatherman